PTC Therapeutics shares are trading lower after the company announced the CHMP has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD.
Portfolio Pulse from Benzinga Newsdesk
PTC Therapeutics shares are trading lower after the Committee for Medicinal Products for Human Use (CHMP) gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD.
September 15, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
PTC Therapeutics' stock price is likely to be negatively impacted in the short term due to the CHMP's negative opinion on the full marketing authorization of Translarna.
The negative opinion from CHMP on the full marketing authorization of Translarna, a product of PTC Therapeutics, is a setback for the company. This could lead to a decrease in investor confidence, resulting in a drop in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100